Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
| 131.03 Delayed Data As of Sep 28 |  -0.20 / -0.15%Today’s Change | 120.64 Today|||52-Week Range 160.96 | -17.75% Year-to-Date |
Latest JAZZ News | Press Releases
| Ligand (LGND) Acquires Certain Assets of Novan for $12.2M Sep 28 / Zacks.com - Paid Partner Content | Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View Sep 19 / Zacks.com - Paid Partner Content |
| Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze Sep 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 131.23 |
| Today’s open | 131.34 |
| Day’s range | 130.84 - 132.42 |
| Volume | 683,645 |
| Average volume (3 months) | 542,214 |
| Market cap | $8.3B |
Data as of 4:00pm ET, 09/28/2023
Growth & Valuation
| Earnings growth (last year) | +35.13% |
| Earnings growth (this year) | +32.57% |
| Earnings growth (next 5 years) | +13.00% |
| Revenue growth (last year) | +18.26% |
| P/E ratio | NM |
| Price/Sales | 2.72 |
| Price/Book | 2.69 |
Competitors
Data as of 4:00pm ET, 09/28/2023
Financials
| Next reporting date | November 7, 2023 |
| EPS forecast (this quarter) | $4.56 |
| Annual revenue (last year) | $3.7B |
| Annual profit (last year) | -$224.1M |
| Net profit margin | -6.12% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Dublin, Dublin |
Forecasts
